<DOC>
	<DOCNO>NCT02605421</DOCNO>
	<brief_summary>This phase II single center study administer two course myeloablative consolidation chemotherapy follow autologous peripheral blood stem cell ( PBSC ) rescue patient high-risk neuroblastoma complete induction chemotherapy ( independent study ) . Ideally , patient begin consolidation chemotherapy later 8 week start Induction Cycle # 5 ; however strongly recommended begin consolidation within 4-6 week start Induction Cycle # 5 .</brief_summary>
	<brief_title>Myeloablative Consolidation Therapy Tandem Autologous Stem Cell Rescue Patients With High-Risk Neuroblastoma</brief_title>
	<detailed_description />
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Less 30 year age diagnosis neuroblastoma No evidence disease progression : defined increase tumor size &gt; 25 % new lesion Recovery last induction course chemotherapy No uncontrolled infection Minimum frozen PBSCs 2 x 10^6 CD34 cells/kg transplant mandatory PBSC 2 x 10^6 CD34 cells/kg backup strongly recommend ( thus , PBSC le 6 x 106 CD34 cells/kg encourage ) . These must collect prior initiation consolidation . Adequate organ function define : Hepatic : aspartate aminotransferase ( AST ) &lt; 3 x upper limit institutional normal alanine aminotransferase ( ALT ) &lt; 3 x upper limit institutional normal ; Renal : Creatinine clearance glomerular filtration rate ( GFR ) &gt; 60 mL/min/1.73m^2 If creatinine clearance perform end induction result &lt; 100 ml/min/1.73m^2 , GFR must perform ; Cardiac : shorten fraction ≥ 27 % ejection fraction ≥ 50 % , clinical congestive heart failure Appropriate write consent adult parent/guardian patient &lt; 18 year age minor information sheet patient &gt; 8 year age</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>High-risk neuroblastoma</keyword>
	<keyword>Neuroblastoma</keyword>
	<keyword>Myeloablative chemotherapy</keyword>
	<keyword>Myeloablative consolidation chemotherapy</keyword>
	<keyword>Autologous peripheral blood stem cell rescue</keyword>
	<keyword>PBSC</keyword>
	<keyword>Autologous stem cell rescue</keyword>
</DOC>